The Histochemical Journal

, Volume 34, Issue 3–4, pp 131–137 | Cite as

Expression of Heparan Sulphate N-deacetylase/N-sulphotransferase by Vascular Smooth Muscle Cells

  • John A. Bingley
  • Ian P. Hayward
  • Adeeb A. Girjes
  • Gordon R. Campbell
  • Donald E. Humphries
  • Jennifer L. Stow
  • Julie H. Campbell
Article

Abstract

Heparan sulphate is an important mediator in determining vascular smooth muscle cell (SMC) phenotype. The sulphation pattern of the heparan sulphate chains is critical to their function. We have examined the initial step in the biosynthesis of the sulphated domains mediated by the enzyme heparan sulphate N-deacetylase/N-sulphotransferase (NDST). Rabbit aortic SMC in primary culture exhibited NDST enzyme activity and expressed NDST-1 in their Golgi apparatus, with maximal expression in SMC 2 days after dispersal in primary culture confirmed by Western blot analysis. Endothelial cells, macrophages and fibroblasts expressed NDST-1 but had generally less intense staining than SMC, although SMC expression decreased with culture. The uninjured rat aorta also showed widespread expression of NDST-1. After balloon de-endothelialisation, NDST-1 could not be detected in SMC of the neointima in the early stages of neointimal formation, but was re-expressed at later time points (after 12 weeks). In human coronary arteries, SMC of the media and the diffuse intimal thickening expressed NDST-1, while SMC in the atherosclerotic plaque were negative for NDST-1. We conclude that SMC may regulate their heparan sulphate sulphation at the level of expression of the enzyme heparan sulphate NDST in a manner related to their phenotypic state.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aikawa J, Esko J (1999) Molecular cloning and expression of a third member of the heparan sulfate/heparin GlcNac N-deacetylase/ N-sulfotransferase family. J Biol Chem 274: 2690–2695.CrossRefPubMedGoogle Scholar
  2. Aikawa J, Grobe K, Tsujimoto M, Esko J (2001) Multiple isozymes of heparan sulfate/heparin GlcNAc N-deacetylase/GlcN N-sulfotransferase. J Biol Chem 276: 5876–5882.CrossRefPubMedGoogle Scholar
  3. Bingley JA, Hayward IP, Campbell GR, Campbell JH (2001) Relationship of glycosaminoglycan and matrix changes to vascular smooth muscle cell phenotype modulation in rabbit arteries following acute injury. J Vasc Surg 33: 155–164.CrossRefPubMedGoogle Scholar
  4. Bingley JA, Hayward IP, Campbell JH, Campbell GR(1998) Arterial heparan sulfate proteoglycans inhibit vascular smooth muscle cell proliferation and phenotype change in vitro and neointimal formation in vivo. J Vasc Surg 28: 308–318.CrossRefPubMedGoogle Scholar
  5. Campbell GR, Campbell JH (1987) Phenotypic modulation of smooth muscle cells in primary culture. In: Campbell JH, Campbell GR, eds. Vascular Smooth Muscle in Culture. Boca Raton: CRC Press, pp 39–56.Google Scholar
  6. Campbell JH, Campbell GR (1993) Culture techniques and their applications to studies of vascular smooth muscle. Clin Sci 85: 510–513.Google Scholar
  7. Campbell JH, Rennick RE, Kalevitch SG, Campbell GR (1992) Heparan sulphate-degrading enzymes induce modulation of smooth muscle phenotype. Exp Cell Res 200: 156–167.CrossRefPubMedGoogle Scholar
  8. Castellot JJ, Wright TC, Karnovsky MJ (1987) Regulation of vascular smooth muscle cell growth by heparin and heparan sulfate. Sem Thromb Haem 13: 489–503.CrossRefGoogle Scholar
  9. Clowes AW, Karnovsky MJ (1977) Suppression by heparin of smooth muscle cell proliferation in injured arteries. Nature 265: 625–626.CrossRefPubMedGoogle Scholar
  10. Dalferes ER, Radhakrishnamurthy B, Ruiz H, Berenson GS (1987) Composition of proteoglycans from human atherosclerotic lesions. Exp Molec Pathol 47: 363–376.CrossRefGoogle Scholar
  11. David G, Bai XM, Van der Schueren B, Cassiman JJ, Van den Berghe H (1992) Developmental changes in heparan sulfate expression: In situ detection with mAbs. J Cell Biol 119: 961–975.CrossRefPubMedGoogle Scholar
  12. Esko JD, Lindahl U (2001) Molecular diversity of heparan sulfate. J Clin Invest 108: 169–173.PubMedGoogle Scholar
  13. Fan G, Xiao L, Cheng L,Wang X, Sun B, Gengxi H (2000) Targeted disruption of NDST-1 gene leads to pulmonary hypoplasia and neonatal respiratory distress in mice. FEBS Lett 467: 7–11.CrossRefPubMedGoogle Scholar
  14. Fritze LMS, Reilly CF, Rosenberg RD (1985) An antiproliferative heparan sulfate species produced by postconfluent smooth muscle cells. J Cell Biol 100: 1041–1049.CrossRefPubMedGoogle Scholar
  15. Girjes AA, Keriakous D, Hayward IP, Campbell GR, Campbell JH (2001) Cloning of genes differentially regulated during change in vascular smooth muscle phenotype. FEBS Lett 509: 341–342.CrossRefPubMedGoogle Scholar
  16. Hein M, Fischer J, Kim DK, Hein L, Pratt RE (1996) Vascular smooth muscle cell phenotype influences glycosaminoglycan composition and growth effects of extracellular matrix. J Vasc Res 33: 433–441.PubMedGoogle Scholar
  17. Hollmann J, Schmidt A, von Bassewitz D-B, Buddecke E (1989) Relationship of sulfated glycosaminoglycans and cholesterol content in normal and atherosclerotic human aorta. Arteriosclerosis 9: 154–158.PubMedGoogle Scholar
  18. Hoover RL, Rosenberg R, Haering W, Karnovsky MJ (1980) Inhibition of rat arterial smooth muscle cell proliferation by heparin II. In vitro studies. Circ Res 47: 578–583.PubMedGoogle Scholar
  19. Humphries DE, Sullivan BM, Aleixo MD, Stow JL (1997) Localization of human heparan glycosaminyl N-deacetylase/N-sulphotransferase to the trans-Golgi network. Biochem J 325: 351–357.PubMedGoogle Scholar
  20. Humphries DE, Wong GW, Friend DS, Gurish MF, Qiu W, Huang C, Sharpe AH, Stevens RL (1999) Heparin is essential for the storage of specific granule proteases in mast cells. Nature 400: 769–772.CrossRefPubMedGoogle Scholar
  21. Li Z-Y, Hirayoshi K, Suzuki Y (2000) Expression of N-deacetylase/ sulfotransferase and 3-O-sulfotransferase in rat alveolar type II cells. Am J Physiol Lung Cell Mol Physiol 279: L292–L301.PubMedGoogle Scholar
  22. Lindahl U, Kusche M, Lidholt K, Oscarrson LG (1989) Biosynthesis of heparin and heparan sulfate. In: Lane DA, Lindahl U, eds. Heparin. London: Arnold, pp 548–574.Google Scholar
  23. Manderson JA, Mosse PRL, Safstrom JA, Young SB, Campbell GR (1989) Balloon catheter injury to rabbit carotid artery. I. Changes in smooth muscle cell phenotype. Arteriosclerosis 9: 289–298.PubMedGoogle Scholar
  24. Mosse PRL, Campbell GR, Wang ZL, Campbell JH (1985) Smooth muscle phenotypic expression in human carotid arteries. Lab Invest 53: 556–562.PubMedGoogle Scholar
  25. Pikas DS, Eriksson I, Kjellén L (2000) Overexpression of different isoforms of glucosaminyl N-deacetylase/N-sulfotransferase results in distinct heparan sulfate N-sulfation patterns. Biochemistry 39: 4552–4558.CrossRefPubMedGoogle Scholar
  26. Radhakrishnamurthy B, Srinivasan SR, Eberle K, Ruiz H, Dalferes ER, Sharma C, Berenson GS (1988) Composition of proteoglycans synthesised by rabbit aortic smooth muscle cells explants in culture and effect of experimental atherosclerosis. Biochim Biophys Acta 964: 231–243.PubMedGoogle Scholar
  27. Ringvall M, Ledin J, Holmborn K, van Kuppevelt T, Ellin F, Eriksson I, Olofsson AM, Kjellen L, Forsberg E (2000) Defective heparan sulfate biosynthesis and neonatal lethality in mice lacking N-deacetylase/ N-sulfotransferase-1. J Biol Chem 275: 25926–25930.CrossRefPubMedGoogle Scholar
  28. Rosenberg RD, Shworak NW, Liu J, Schwartz JJ, Zhang L (1997) Heparan sulfate proteoglycans of the cardiovascular system. J Clin Invest 99: 2062–2070.CrossRefPubMedGoogle Scholar
  29. Salmivirta M, Lidholt K, Lindahl U (1996) Heparan sulfate: A piece of information. FASEB J 10: 1270–1279.PubMedGoogle Scholar
  30. Schmidt A, Buddecke E (1990) Bovine aortic smooth muscle cells synthesize two functionally different proteoheparan sulphate species. Exp Cell Res 189: 269–275.CrossRefPubMedGoogle Scholar
  31. Schmidt A, Lemming G, Yoshida K, Buddecke E (1992) Molecular organisation and antiproliferative domains of arterial tissue heparan sulfate. Eur J Cell Biol 59: 322–328.PubMedGoogle Scholar
  32. Toma L, Berninsone P, Hirschberg CB (1998) The putative heparinspecific N-acetylglucosaminyl N-deacetylase/N-sulfotransferase also occurs in non-heparin-producing cells. J Biol Chem 273: 22458–22465.CrossRefPubMedGoogle Scholar
  33. Wight TN (1989) Cell Biology of Arterial Proteoglycans. Arteriosclerosis 9: 1–20.PubMedGoogle Scholar
  34. Williams SP, Mason RM (1991) Modulation of proteoglycan synthesis by bovine vascular smooth muscle cell proliferation and treatment with heparin. Arch Biochem Biophys 287: 386–396.CrossRefPubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 2002

Authors and Affiliations

  • John A. Bingley
    • 1
  • Ian P. Hayward
    • 1
  • Adeeb A. Girjes
    • 1
  • Gordon R. Campbell
    • 1
  • Donald E. Humphries
    • 2
  • Jennifer L. Stow
    • 3
  • Julie H. Campbell
    • 1
  1. 1.Centre for Research in Vascular Biology, School of Biomedical SciencesUniversity of QueenslandBrisbaneAustralia
  2. 2.VA Medical CenterBostonUSA
  3. 3.Institute for Molecular BioscienceUniversity of QueenslandBrisbaneAustralia

Personalised recommendations